Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system.
نویسندگان
چکیده
How the immune system recognizes endogenously arising tumors and elicits adaptive immune responses against nonmutated tumor-associated Ags is poorly understood. In search of intrinsic factors contributing to the immunogenicity of the tumor-associated Ag NY-ESO-1, we found that the NY-ESO-1 protein binds to the surface of immature dendritic cells (DC), macrophages, and monocytes, but not to that of B cells or T cells. Using immunoprecipitation coupled with tandem mass spectrometry, we isolated DC surface calreticulin as the receptor for NY-ESO-1. Calreticulin Abs blocked NY-ESO-1 binding on immature DC and its cross-presentation to CD8+ T cells in vitro. Calreticulin/NY-ESO-1 interactions provide a direct link between NY-ESO-1, the innate immune system, and, potentially, the adaptive immune response against NY-ESO-1.
منابع مشابه
The Efficacy of Toll-Like Receptors in Awakening Dendritic Cell/Natural Killer Cell System for Eradication of Tumors
Natural killer (NK) cells are effector cells of the innate immune system that exert direct cytotoxic functions. Ubiquitously-expressed toll-like receptors (TLRs) have been recognized as one of the major components promoting dendritic cell (DC) maturation, which may induce polarized immune responses beneficial to cancer immunotherapy. TLR-activated NK cells and DCs are prerequisite for robust ac...
متن کاملUptake of Autologous and Allogenic Tumor Cell Antigens by Dendritic Cells
Background: Dendritic cells (DCs) are professional antigen presenting cells (APCs), and there is considerable interest in their application as a cellular adjuvant for cancer immunotherapy. Previous studies indirectly demonstrated that DCs were able to take up tumor lysate (crude soluble tumor antigens) and also cross-present tumor associated antigens (TAA) which elicits anti-tumor immune respo...
متن کاملA novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.
We investigated whether antibodies against intracellular tumor-associated antigens support tumor-specific immunity when administered together with a treatment that destroys the tumor. We propose that released antigens form immune complexes with the antibodies, which are then efficiently taken up by dendritic cells. We cloned the first human monoclonal antibodies against the Cancer/Testis (CT) a...
متن کاملDhodapkar 1..9
, 232ra51 (2014); 6 Sci Transl Med et al. Madhav V. Dhodapkar NY-ESO-1 to the Dendritic Cell Receptor DEC-205 Induction of Antigen-Specific Immunity with a Vaccine Targeting Editor's Summary additional avenue to boost the immune response to cancer. these data can be reproduced in larger trials, this study suggests that targeting antigen to dendritic cells could be an either stable disease or d...
متن کاملIntracellular tumor-associated antigens represent effective targets for passive immunotherapy.
Monoclonal antibody (mAb) therapy against tumor antigens expressed on the tumor surface is associated with clinical benefit. However, many tumor antigens are intracellular molecules that generally would not be considered suitable targets for mAb therapy. In this study, we provide evidence challenging this view through an investigation of the efficacy of mAb directed against NY-ESO-1, a widely e...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of immunology
دوره 177 6 شماره
صفحات -
تاریخ انتشار 2006